News | Magnetic Resonance Imaging (MRI) | May 10, 2016

MRI Stronger Predictor of Major Adverse Cardiovascular Events than SPECT

Study of 752 patients finds cardiac magnetic resonance better predicts risk at five year follow-up

cardiac magnetic resonance, CMR, SPECT, major adverse cardiovascular events, MACE predictor, Annals of Internal Medicine study

May 10, 2016 — Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT) at five years follow-up. The findings are published in Annals of Internal Medicine.

CMR is an MRI scan that focuses on the area around the heart. Unlike SPECT, CMR does not involve ionizing radiation and the large CE-MARC (Clinical Evaluation of Magnetic Resonance imaging in Coronary heart disease) study demonstrated that CMR had high diagnostic accuracy, with higher sensitivity and negative predictive value compared with SPECT.

However, data on the prognostic value of CMR remain limited. A predefined objective of CE-MARC was to assess the ability of CMR and SPECT to predict MACE at five-year follow-up. To do so, researchers studied 752 patients from the CE-MARC study who were being investigated for suspected coronary heart disease. The patients were scheduled to undergo CMR and SPECT in random order, followed by X-ray coronary angiography (the reference standard) within four weeks. The investigators followed up with patients every year for five years to assess for MACE.

The researchers found that at five-year follow-up, CMR was a stronger predictor of risk for MACE than SPECT, independent of clinical cardiovascular risk factors, angiography result or initial patient treatment. The researchers conclude that CMR should be considered a robust alternative to SPECT for the diagnosis and management of patients with suspected coronary heart disease.

For more information: www.annals.org


Additional Content

News | Cardiac Imaging

Nov. 1, 2026 — GE HealthCare recently introduced Allia Celeo,* a ceiling-mounted image guiding system, at the ...

Home November 05, 2026
Home
News | Cardiac Imaging

Nov. 2, 2026 – Conavi Medical Corp. has announced the completion of the first U.S. placement and clinical cases with ...

Home November 03, 2026
Home
News | Cardiac Imaging

Oct. 6, 2026 — Riverain Technologies has announced that its FDA-cleared ClearRead Chest suite will be available through ...

Home October 08, 2026
Home
News | Cardiac Imaging

Aug. 12, 2026 — Salus Scientific has launched its Clinical Insights Series, a new publication platform designed to share ...

Home August 17, 2026
Home
News | Cardiac Imaging

Aug. 12, 2026 — Ventripoint Diagnostics is expanding subscription-based access to its VMS+ 4.0, its FDA-cleared platform ...

Home August 14, 2026
Home
Subscribe Now